Patents by Inventor Rajesh Jain
Rajesh Jain has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160345914Abstract: Described is an infant monitoring and alerting system capable of determining an absence of movement by an infant. When an absence of movement is detected the monitor attempts to stimulate movement using stimuli that may include a vibration, an audible alert, or a visual alert. If no movement is detected in response to the stimuli, the monitor may provide another instance of stimuli which may include stimuli at an elevated intensity or additional and/or different stimuli. The additional instance of stimuli may further attempt to stimulate movement by the infant and may also function as an alert to the caregiver that their attention may be required.Type: ApplicationFiled: June 1, 2015Publication date: December 1, 2016Inventor: Rajesh Jain
-
Patent number: 9402808Abstract: The present invention relates to liquid oral pharmaceutical compositions of lanthanum and its pharmaceutically acceptable salts thereof. The present invention further relates to preparation of liquid oral pharmaceutical compositions of lanthanum and its salts and also provides use of such compositions in treating hyperphosphatemia in patients.Type: GrantFiled: January 17, 2012Date of Patent: August 2, 2016Assignee: PANACEA BIOTEC LIMITEDInventors: Rajesh Jain, Sarabjit Singh, Paramjit Singh, Pirthi Pal Singh
-
Publication number: 20160143046Abstract: To schedule user equipments (UEs) in a scheduling period, for each of X cells in a carrier aggregation (CA) system relative priorities of data bearers are determined. Each data bearer is associated with a respective UE having buffered data and at least one of the UEs is a CA-UE that is allowed radio resource allocation to its associated data bearers in at least two of the cells. For each CA-UE, the buffered data of the CA-UE is distributed across those cells in which the CA-UE and its associated bearers are allowed resource allocation using a measure of total data throughput for each of those cells. For each of the X cells resources are allocated to the data bearers according to the relative priorities such that for each CA-UE the resources allocated to its associated data bearers across those cells are sufficient to carry the buffered data as distributed.Type: ApplicationFiled: November 18, 2014Publication date: May 19, 2016Inventors: Rajiv GUPTA, Mayank Kumar RASTOGI, Rajesh JAIN, Gaurav GOEL, Tauheed AHMED
-
Publication number: 20160142933Abstract: User equipments (UEs) may be scheduled by, in a cell, determining relative priorities of data radio bearers (DRBs), each DRB associated with an active UE. A limit is established dividing radio resources available for allocation in the cell during a scheduling period into at least a first limited portion and a second remaining portion. According to the determined relative priorities: a) up to the first limited portion of the radio resources are allocated to only the DRBs that have a guaranteed bit rate (GBR), and thereafter b) the second remaining portion of the radio resources are allocated to only the DRBs which have not been fully allocated from the first limited portion. In carrier aggregation the radio resources are allocated in turn in each different cell per step a) and thereafter in turn in each different cell per step b).Type: ApplicationFiled: November 14, 2014Publication date: May 19, 2016Inventors: Mayank Kumar RASTOGI, Rajiv GUPTA, Rajesh JAIN, Tauheed AHMED
-
Patent number: 9292423Abstract: A compatibility service monitors programs to detect compatibility issues. The compatibility service provides users, such as developers, with notifications of compatibility issues a program may experience when the program executes on a particular device and/or uses a particular operating system. In some configurations, the compatibility service detects compatibility issues by performing tests on programs using a testing service. The compatibility service may also receive notifications of incompatibilities from different sources. For example, the compatibility service may receive notifications of incompatibilities from other users (e.g., developers), web sites, and the like. The compatibility service may proactively notify developers of compatibility issues for their programs. For example, one developer may request to be notified of all detected compatibility issues, whereas another developer might request to be notified of compatibility issues that are above some specified severity level of incompatibility.Type: GrantFiled: March 11, 2015Date of Patent: March 22, 2016Assignee: Amazon Technologies, Inc.Inventors: Japan Shailesh Doshi, Rajesh Jain, Sanyu Kiruluta
-
Patent number: 9133116Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system, preferably by modulating neurological and/or psychiatric targets (GPCR and/or non-GPCR).Type: GrantFiled: September 27, 2011Date of Patent: September 15, 2015Assignee: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Nishan Singh, Sudhir Kumar Sharma
-
Patent number: 9018249Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).Type: GrantFiled: September 12, 2012Date of Patent: April 28, 2015Assignee: Panacea Biotec LimitedInventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Gurmeet Kaur Nanda, Sastry V. R. S. Thungathurthi, Nishan Singh, Sudhir Kumar Sharma
-
Publication number: 20140378540Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).Type: ApplicationFiled: September 12, 2012Publication date: December 25, 2014Inventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Gurmeet Kaur Nanda, Sastry V. R. S Thungathurthi, Nishan Singh, Sudhir Kumar Sharma
-
Patent number: 8906913Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof.Type: GrantFiled: June 22, 2010Date of Patent: December 9, 2014Assignee: Panacea Biotec LimitedInventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Gurmeet Kaur, Sandeep Kanwar, Nishan Singh, Gurmeet Kaur Nanda, Sitaram Kumar Magadi, Sudhir Kumar Sharma
-
Patent number: 8841306Abstract: The present invention relates to novel phenyl oxazolidinone compounds of formula I, their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of formula I or their pharmaceutically acceptable analogs, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of formula I and methods of using them. The compounds of the present invention are useful as antimicrobial agents, effective against a number of aerobic and/or anaerobic Gram positive and/or Gram negative pathogens such as multi drug resistant species of Staphylococcus, Streptococcus, Enterococcus, Bacterioides, Clostridia, H.Type: GrantFiled: November 18, 2009Date of Patent: September 23, 2014Assignee: Panacea Biotec Ltd.Inventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Sandeep Kanwar, Sitaram Kumar Magadi, Sudhir Kumar Sharma
-
Publication number: 20140228303Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising novel compounds of Formula I and methods of treating or preventing one or more conditions or diseases that may be regulated or normalized via inhibition of Sodium Glucose Cotransporter-2 (SGLT-2).Type: ApplicationFiled: June 13, 2012Publication date: August 14, 2014Applicant: Panacea Biotec LtdInventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Gurmeet Kaur Nanda, Sastry V. R. S Thungathurthi, Nishan Singh, Sudhir Kumar Sharma
-
Publication number: 20130302383Abstract: The present invention relates to liquid oral pharmaceutical compositions of lanthanum and its pharmaceutically acceptable salts thereof. The present invention further relates to preparation of liquid oral pharmaceutical compositions of lanthanum and its salts and also provides use of such compositions in treating hyperphosphatemia in patients.Type: ApplicationFiled: January 17, 2012Publication date: November 14, 2013Inventors: Rajesh Jain, Sarabjit Singh, Paramjit Singh, Pirthi Pal Singh
-
Publication number: 20130280324Abstract: The present invention relates to stable once daily sustained release pharmaceutical compositions comprising pregabalin or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable excipient wherein pharmaceutical composition is bioequivalent to conventional immediate release formulation of pregabalin administered twice daily. The present invention further relates to a composition comprising pregabalin and sugar esters as release retarding agent for maintaining uniform release rate of the drug and process for the preparation of such oral sustained release formulations.Type: ApplicationFiled: September 15, 2011Publication date: October 24, 2013Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Sarabjit Singh, Shivanand Puthli
-
Patent number: 8551451Abstract: The present invention relates to a combination vaccine comprising a mixture of antigens for protection against diseases such as diphtheria, tetanus, acellular pertussis, and infections caused by Haemophilus influenzae and polio viruses. The present invention also relates to inclusion of antigens for protection against infections caused Hepatitis virus and other pathogens, such that administration of the vaccine can simultaneously immunize a subject against more than one pathogen. The invention in particular relates to a fully liquid stable combination vaccine comprising the antigens as indicated above and the methods for manufacturing the same.Type: GrantFiled: October 23, 2009Date of Patent: October 8, 2013Assignee: Panacea Biotec LimitedInventors: Rajesh Jain, Sukhjeet Singh, Lavit Jambu
-
Publication number: 20130253029Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention further provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more disorders of the central and/or peripheral nervous system, preferably by modulating neurological and/or psychiatric targets (GPCR and/or non-GPCR).Type: ApplicationFiled: September 27, 2011Publication date: September 26, 2013Applicant: Panacea Biotec LtdInventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Nishan Singh, Sudhir Kumar Sharma
-
Patent number: 8455479Abstract: The present invention relates to novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers including R and S isomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The invention also relates to the processes for the synthesis of novel compounds of Formula I, their pharmaceutically acceptable derivatives, tautomeric forms, stereoisomers, polymorphs, prodrugs, metabolites, salts or solvates thereof. The present invention also provides pharmaceutical compositions comprising compounds of Formula I and methods of treating or preventing one or more conditions that may be regulated or normalized via inhibition of dipeptidyl peptidase IV (DPP-IV).Type: GrantFiled: January 23, 2009Date of Patent: June 4, 2013Assignee: Panacea Biotec LimitedInventors: Rajesh Jain, Sanjay Trehan, Jagattaran Das, Nishan Singh, Gurmeet Kaur Nanda, Sitaram Kumar Magadi, Sudhir Kumar Sharma
-
Publication number: 20120271443Abstract: A method of automatic manufacturability evaluation of plastic models comprises generation of a likely pulling direction, recognition of common features on plastic parts, and then applying manufacturability rules The manufacturability rules can be specified and customized through user specified rule parameters and depend upon the geometric parameters of the recognized features. A system comprises a user interface for selection and customization of DFX (Design for ‘X’) rules for evaluation of a design. The system includes a user interface integrated with a CAD system for receiving the CAD data and displaying the results to the user. Geometry analysis engines are integrated into the system, for extracting the various features and corresponding parameters required as input to the manufacturability rules. The system further involves extensible interfaces for rules and analysis engines which allows users to write their own customized rules and engines and integrate these into the CAD based DFX evaluation system.Type: ApplicationFiled: July 6, 2012Publication date: October 25, 2012Applicant: GEOMETRIC LIMITEDInventors: Bhaskar SINHA, Ashish PATIL, Ajay A. DESHPANDE, Alpana SHARMA, Christine ZUZART, Sameer KONDEJKAR, Rajesh JAIN, Nitin UMAP, Rahul RAJADHYAKSHA
-
Patent number: 8219230Abstract: A method of automatic manufacturability evaluation of plastic models comprises generation of a likely pulling direction, recognition of common features on plastic parts, and then applying manufacturability rules The manufacturability rules can be specified and customized through user specified rule parameters and depend upon the geometric parameters of the recognized features. A system comprises a user interface for selection and customization of DFX (Design for ‘X’) rules for evaluation of a design. The system includes a user interface integrated with a CAD system for receiving the CAD data and displaying the results to the user. Geometry analysis engines are integrated into the system, for extracting the various features and corresponding parameters required as input to the manufacturability rules. The system further involves extensible interfaces for rules and analysis engines which allows users to write their own customized rules and engines and integrate these into the CAD based DFX evaluation system.Type: GrantFiled: June 9, 2010Date of Patent: July 10, 2012Assignee: Geometric LimitedInventors: Bhaskar Sinha, Ashish Patil, Ajay Deshpande, Alpana Sharma, Christine Zuzart, Sameer Kondejkar, Rajesh Jain, Nitin Umap, Rahul Rajadhyaksha
-
Publication number: 20120141525Abstract: The present invention relates to a novel influenza vaccine, a novel plasmid for preparing the same and a novel dosage form comprising the same. The present invention in particular relates to a recombinant modified vaccinia Ankara (MVA) virus comprising and capable of simultaneously expressing a cassette of at least four foreign genes from influenza virus, specifically an avian influenza virus, wherein the said genes are inserted at a non-essential site, within the MVA genome. The invention further relates to a recombinant modified vaccinia Ankara (MVA) virus comprising and capable of simultaneously expressing a cassette of not less than two foreign genes from influenza virus, wherein the said genes are inserted at a non-essential site, within the MVA genome, with the provision that at least one foreign gene is either PB2 or M2e. The invention also provides composition and methods of making the universal influenza vaccine.Type: ApplicationFiled: May 17, 2010Publication date: June 7, 2012Applicant: PANACEA BIOTEC LIMITEDInventors: Rajesh Jain, Virender Kumar Vinayak, Nidhi Shukla, Neeraj Aggarwal, Rajan Mehta
-
Publication number: 20120010158Abstract: The present invention relates to Tumor Necrosis Factor-alpha (TNF-alpha or TNF-?) inhibiting peptides and process for the preparation thereof. The present invention further relates to a pharmaceutical composition comprising TNF-alpha inhibiting peptides of the present invention and uses thereof in treating TNF-alpha mediated inflammatory disorders.Type: ApplicationFiled: November 5, 2009Publication date: January 12, 2012Applicant: PANACEA BIOTEC LTD.Inventors: Rajesh Jain, Virendra Kumar Vinayak, Shweta Dubey, Shudhanand Prasad, Vijay Goel, Rahul Jain